Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05493826 | COMPLETED | Cutaneous Squamous Cell Carcinoma

Real World Study on the Use of Cemiplimab in Adult Patients in UK
Sponsor:

Sanofi

Brief Summary:

The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.

Condition or disease

Cutaneous Squamous Cell Carcinoma

Intervention/treatment

No intervention

Detailed Description:

Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020, will be followed for a minimum of 12 and a maximum of 36 months from initiation of cemiplimab.

Study Type : OBSERVATIONAL
Estimated Enrollment : 110 participants
Official Title : Real-world Evidence Study on the Early Use of Cemiplimab in the UK: REACT-CEMI (Real World Evidence of Advanced CSCC Treatment - With CEMIplimab)
Actual Study Start Date : 2022-07-18
Estimated Primary Completion Date : 2022-11-01
Estimated Study Completion Date : 2022-11-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients aged \>=18 years at initiation of cemiplimab.
  • * Patients treated with \>=1 dose of cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation according to routine practice.
  • * Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020.
Exclusion Criteria
  • * Patients who are known to have opted out of participation in any research (as required for compliance with GDPR).
  • * Patients participating in any form of investigative study (e.g., clinical trials) during the post-index observation period.
Real World Study on the Use of Cemiplimab in Adult Patients in UK

Location Details

NCT05493826

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United Kingdom, Berkshire

Sanofi-Aventis UK

Reading, Berkshire, United Kingdom, RG6 1PT